Who are Protamin administration's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Protamine ratio dose, PO continuous infusion of Protamine, Protamine fixed dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/protamin-administration.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Protamin administration — Competitive Intelligence Brief

Protamin administration (Protamin administration) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Heparin antagonist / Anticoagulant reversal agent. Area: Cardiovascular / Hemostasis.

marketed Heparin antagonist / Anticoagulant reversal agent Heparin (unfractionated heparin) Cardiovascular / Hemostasis Small molecule Live · refreshed every 30 min

Target snapshot

Protamin administration (Protamin administration) — University Hospital, Strasbourg, France. Protamine is a positively charged protein that binds to and neutralizes the anticoagulant effects of heparin by forming an inactive complex.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Protamin administration TARGET	Protamin administration	University Hospital, Strasbourg, France	marketed	Heparin antagonist / Anticoagulant reversal agent	Heparin (unfractionated heparin)
Protamine ratio dose	Protamine ratio dose	University of Miami	marketed	Heparin antagonist / Anticoagulant reversal agent	Heparin (unfractionated and low-molecular-weight heparin)
PO continuous infusion of Protamine	PO continuous infusion of Protamine	SANE-Society of Anesthesiology	marketed	Heparin antagonist / Anticoagulant reversal agent	Heparin (unfractionated and low-molecular-weight heparin)
Protamine fixed dose	Protamine fixed dose	University of Miami	marketed	Heparin antagonist / Anticoagulant reversal agent	Heparin (unfractionated heparin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Heparin antagonist / Anticoagulant reversal agent class)

University of Miami · 2 drugs in this class
SANE-Society of Anesthesiology · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Protamin administration — Competitive Intelligence Brief. https://druglandscape.com/ci/protamin-administration. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab